IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1051-1075 out of 1298.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

Public Release: 27-Feb-2014
Developmental Cell
Discoveries point to more powerful cancer treatments, fewer side effects
A Rutgers study suggests a way to make chemotherapy and radiation more effective as cancer treatments while eliminating debilitating side effects. The approach eliminates eEF2K -- an enzyme that influences the rates at which proteins are created in the human body. The enzyme's presence tends to leave cells less robust than they otherwise would be, and that added weakness leaves healthy cells vulnerable to being poisoned by chemo and radiation.

Contact: Rob Forman
robert.forman@rutgers.edu
973-972-7276
Rutgers University

Public Release: 27-Feb-2014
Science Translational Medicine
CNIO researchers discover new strategies for the treatment of psoriasis
Almost 10 years ago, the group led by Erwin Wagner developed genetically modified mice showing symptoms very reminiscent to psoriasis. After publishing this discovery in Nature, the researchers decided to use this mouse model to study the underlying molecular pathways involved in disease development, and to look for innovative and efficient therapies. Now the group has discovered two possible novel treatments, based on existing pharmacological compounds, which are likely to cause fewer side effects.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 27-Feb-2014
Gene Therapy
Cancer vaccine could use immune system to fight tumors
Cincinnati Cancer Center and University of Cincinnati Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.
NIH/National Cancer Institute, LCS Foundation Cincinnati, University of CincinnatiNIH/National Cancer Institute, LCS Foundation Cincinnati, University of Cincinnati

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 27-Feb-2014
Science
Researchers discover unusual genetic mutation linked to adolescent liver cancer
In the race for better treatments and possible cures, rare diseases are often left behind. In a collaboration of researchers at The Rockefeller University, Memorial Sloan Kettering Cancer Center and the New York Genome Center, an unusual mutation has been found that is strongly linked to one such disease: a rare liver cancer that affects teens and young adults.
Fibrolamellar Cancer Foundation

Contact: Zach Veilleux
zveilleux@rockefeller.edu
212-327-8982
Rockefeller University

Public Release: 27-Feb-2014
A world free from cancers: Probable, possible, or preposterous?
A panel of leading health, economics and policy experts today discussed the prospects for a future where cancers are rendered manageable or even eradicated and the variables affecting progress toward that goal so that cancer patients are able to lead normal, productive lives -- and thus be 'free from' their cancers. The forum was hosted by Research!America and the Pancreatic Cancer Action Network. The event, titled, 'A World Free from Cancers: Probable, Possible, or Preposterous?' was held at the New York Academy of Sciences.

Contact: Suzanne Ffolkes
sffolkes@researchamerica.org
571-482-2710
Research!America

Public Release: 27-Feb-2014
Journal of Biological Chemistry
Scientists discover new protein involved in lung cancer
The research by the Manchester team looked at glucocorticoids, the hormones that regulate inflammation and energy production in cells in the body. In lung cancer these hormones are known to play a role in controlling cell growth. Glucocorticoids work through receptors, and this new research reveals how these receptors work.

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 27-Feb-2014
Reproductive Toxicology
Bisphenol A (BPA) at very low levels can adversely affect developing organs in primates
Bisphenol A is a chemical that is used in a wide variety of consumer products and exhibits hormone-like properties. Fetuses, infants, children or adults exposed to the chemical have been shown to exhibit numerous abnormalities, including cancer, as well as reproductive, immune and brain-behavior problems. Now, researchers at the University of Missouri have determined that daily exposure to very low concentrations of bisphenol A by pregnant females also can cause fetal abnormalities in primates.
NIH/National Institute of Environmental Health Sciences

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia

Public Release: 27-Feb-2014
Oncogene
Targeting metabolism to develop new prostate cancer treatments
A University of Houston scientist is working to develop the next generation of prostate cancer therapies targeted at metabolism. Daniel Frigo is looking at a cascade of biochemical reactions inside the cell, focusing on an enzyme considered a master regulator of metabolism. Frigo wants to unlock more effective and less harmful treatments. Funded by the Department of Defense and National Institutes of Health, he most recently received another grant last week from Golfers Against Cancer.
Golfers Against Cancer, US Department of Defense, National Institutes of Health, and others

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston

Public Release: 27-Feb-2014
Cancer Research
Study identifies possible new target for future brain cancer drugs
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat glioblastoma, the most frequent and lethal form of brain cancer. The findings suggest that the protein PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease.
NIH/National Institute of Neurological Disorders and Stroke, Ohio Cancer Research Associates, V Foundation

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 27-Feb-2014
Cell
Study reveals mechanisms cancer cells use to establish metastatic brain tumors
New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.
National Institutes of Health, US Department of Defense Innovator Award, Alan and Sandra Gerry Metastasis Research Initiative

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center

Public Release: 27-Feb-2014
Lancet
Nobelist James Watson proposes an unconventional view of type 2 diabetes causation
At 85, Nobel laureate James D. Watson, the co-discoverer of the double-helix structure of DNA, continues to advance intriguing scientific ideas. His latest, a hypothesis on the causation of type 2 diabetes, is to appear 7 p.m. Thursday US time in the online pages of The Lancet, the prestigious British medical journal.

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 26-Feb-2014
Nature
Sunburns strike twice
Melanoma is particularly dangerous because it can form metastases in vital organs such as the lungs, liver or brain. UV radiation is considered to be the most significant triggering factor. An interdisciplinary team of researchers from the University Hospital and the LIMES Institute of the University of Bonn has now discovered that sunburns contribute not only through direct alteration of pigment cell genomes but also indirectly through inflammatory processes in the surrounding tissue. The results are now being published in Nature.

Contact: Dr. Thomas Tüting
Thomas.Tueting@ukb.uni-bonn.de
49-228-287-15370
University of Bonn

Public Release: 26-Feb-2014
Journal of Thoracic Oncology
Hormone therapy linked to better survival after lung cancer diagnosis in women
Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. The combination of estrogen plus progesterone and the use of long-term hormone therapy were associated with the most significant improvements in survival.

Contact: Kristin Richeimer
kristin.richeimer@iaslc.org
720-325-2953
International Association for the Study of Lung Cancer

Public Release: 26-Feb-2014
Journal of Cancer Survivorship
Follow-up care for older breast cancer survivors needs to be all-encompassing
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. These findings, by lead author Nadia Obi, who collaborated with the group of Professor Chang-Claude, were published in Springer's Journal of Cancer Survivorship.
Deutsche Krebshilfe e.V

Contact: Saskia Rohmer
saskia.rohmer@springer.com
49-622-148-78414
Springer

Public Release: 26-Feb-2014
PLOS ONE
Breast cancer cells less likely to spread when one gene is turned off
New research suggests that a protein only recently linked to cancer has a significant effect on the risk that breast cancer will spread, and that lowering the protein's level in cell cultures and mice reduces chances for the disease to extend beyond the initial tumor.
National Science Foundation

Contact: Douglas Kniss
Kniss.1@osu.edu
614-293-4496
Ohio State University

Public Release: 26-Feb-2014
Inorganic Chemistry
Caffeine-based gold compounds are potential tools in the fight against cancer
The side effects of ingesting too much caffeine -- restlessness, increased heart rate, having trouble sleeping -- are well-known, but recent research has shown that the stimulant also has a good side. It can kill cancer cells. Now, researchers report in the American Chemical Society journal Inorganic Chemistry that combining a caffeine-based compound with a small amount of gold could someday be used as an anti-cancer agent.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 26-Feb-2014
Science Translational Medicine
Beta-catenin alters T cells in lasting and harmful ways
Activation of beta-catenin, the primary mediator of the ubiquitous Wnt signaling pathway, alters the immune system in lasting and harmful ways, causing chronic inflammation in the intestine and colon, eventually leading to cancer. Researchers unravel the mechanism of this transition.
National Institutes of Health, American Cancer Society, Lurie Comprehensive Cancer Center

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center

Public Release: 26-Feb-2014
Cancer Research
Second-most common breast cancer subtype may benefit from personalized treatment approach
The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment. Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma.
Breast Cancer Research Foundation, Noreen Fraser Foundation, US Department of Defense, Pennsylvania Department of Health

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 26-Feb-2014
Molecular Cell
Fox Chase researchers discover new mechanism of gene regulation
Additional insights into how cancer cells use PARP1 enzyme to resist current therapies may also point to the next generation of cancer drugs.
National Institutes of Health

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center

Public Release: 26-Feb-2014
Clinical Gastroenterology and Hepatology
Screen some patients with acute pancreatitis for pancreatic cancer, SLU researchers suggest
Banke Agarwal, M.D., associate professor of gastroenterology and hepatology at Saint Louis University, says there is a much higher risk of pancreatic cancer in patients with acute pancreatitis than commonly believed.

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University

Public Release: 26-Feb-2014
Journal of Experimental Medicine
Experimental treatment developed at UCLA eradicates acute leukemia in mice
A team of scientists from the University of California Los Angeles Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 26-Feb-2014
Journal of American Chemical Society
Finding a few foes among billions of cellular friends
Beating cancer is all about early detection, and new research from the University of South Carolina is another step forward in catching the disease early. A team of chemists is reporting a new way to detect just a handful of lurking tumor cells, which can be outnumbered a billion to one in the bloodstream by healthy cells.

Contact: Steven Powell
spowell2@mailbox.sc.edu
803-777-1923
University of South Carolina

Public Release: 26-Feb-2014
Journal of Synchrotron Radiation
Nanoscale freezing leads to better imaging
New X-ray tool allows for more sensitivity to trace metals, such as those that cause cancer, in whole cells and tissues.
National Institutes of Health, Department of Energy

Contact: Tona Kunz
tkunz@anl.gov
630-252-5560
DOE/Argonne National Laboratory

Public Release: 26-Feb-2014
Supportive Care in Cancer
Can a simple handshake predict cancer survival rates?
New acquaintances are often judged by their handshake. Research has now recognized the simple squeeze as an important diagnostic tool in assessing strength and quality of life among critical care patients.

Contact: Clea Desjardins
clea.desjardins@concordia.ca
51-484-824-245-068
Concordia University

Public Release: 26-Feb-2014
Genome Research
New advances in the chronic lymphocytic leukaemia genome
The Chronic Lymphatic Leukaemia (CLL) Genome Consortium moves closer to the functional study of the genome and its application for improving the treatment of the disease. Researchers from the Spanish CLL Consortium identify functional differences in leukaemia cells. Their findings are published in the journal Genome Research and provide a new classification of the disease that could, eventually, improve predictions of the best time for starting treatment.
Ministry of Economy and Competitiveness, Spain and the International Cancer Genome Consortium

Contact: Juan Manuel Sarasua
juan.sarasua@crg.eu
Center for Genomic Regulation

Showing releases 1051-1075 out of 1298.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

  Search News Releases

     

 

 

EurekAlert!